Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
On Friday May 8, 2009, 12:31 pm EDT
BEIJING, May 8 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA
), a leading provider of vaccines in China, today announced that it will host a conference call on Friday, May 15, 2009 at 9:00 a.m. ET to review the Company's first quarter financial results for the period ended March 31, 2009 and provide an update on recent corporate developments.
To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 12:00 p.m. ET on May 15, until May 29, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 322891.
A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com
. A webcast replay can be accessed on the corporate website beginning May 15, 2009 and the replay will remain available for 30 days.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), and Anflu® (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
Contact Information: Investors:
Helen G. Yang Amy Glynn/Sara Ephraim
Sinovac Biotech Ltd. The Ruth Group
Phone: +86-10-82890088 Ext. 871 (646) 536-7023/7002
The Ruth Group